CN117320750A - 用抗神经酰胺抗体增强伤口愈合 - Google Patents

用抗神经酰胺抗体增强伤口愈合 Download PDF

Info

Publication number
CN117320750A
CN117320750A CN202280032286.4A CN202280032286A CN117320750A CN 117320750 A CN117320750 A CN 117320750A CN 202280032286 A CN202280032286 A CN 202280032286A CN 117320750 A CN117320750 A CN 117320750A
Authority
CN
China
Prior art keywords
seq
amino acid
acid sequence
antigen
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280032286.4A
Other languages
English (en)
Chinese (zh)
Inventor
R·科莱斯尼克
J·布西克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer And Related Disease Memorial Hospital
Michigan State University
Memorial Sloan Kettering Cancer Center
Original Assignee
Cancer And Related Disease Memorial Hospital
Michigan State University
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer And Related Disease Memorial Hospital, Michigan State University, Memorial Sloan Kettering Cancer Center filed Critical Cancer And Related Disease Memorial Hospital
Publication of CN117320750A publication Critical patent/CN117320750A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202280032286.4A 2021-03-16 2022-03-15 用抗神经酰胺抗体增强伤口愈合 Pending CN117320750A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163161758P 2021-03-16 2021-03-16
US63/161,758 2021-03-16
PCT/US2022/020385 WO2022197703A1 (en) 2021-03-16 2022-03-15 Wound healing enhancement with anti-ceramide antibodies

Publications (1)

Publication Number Publication Date
CN117320750A true CN117320750A (zh) 2023-12-29

Family

ID=83321040

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280032286.4A Pending CN117320750A (zh) 2021-03-16 2022-03-15 用抗神经酰胺抗体增强伤口愈合

Country Status (10)

Country Link
US (1) US20240158487A1 (cg-RX-API-DMAC7.html)
EP (1) EP4308231A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024511079A (cg-RX-API-DMAC7.html)
KR (1) KR20230162788A (cg-RX-API-DMAC7.html)
CN (1) CN117320750A (cg-RX-API-DMAC7.html)
BR (1) BR112023018758A2 (cg-RX-API-DMAC7.html)
CA (1) CA3212333A1 (cg-RX-API-DMAC7.html)
IL (1) IL305920A (cg-RX-API-DMAC7.html)
MX (1) MX2023010858A (cg-RX-API-DMAC7.html)
WO (1) WO2022197703A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12655229B2 (en) 2020-03-18 2026-06-16 Memorial Sloan Kettering Cancer Center Anti-ceramide antibodies

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010027802A2 (en) * 2008-08-25 2010-03-11 New York University Methods for treating diabetic wounds
US20100239572A1 (en) * 2007-05-06 2010-09-23 Sloan Kettering Institute For Cancer Research Methods for treating and preventing gi syndrome and graft versus host disease
US20170335014A1 (en) * 2014-08-07 2017-11-23 Memorial Sloan-Kettering Cancer Center Anti-ceramide antibodies

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10722577B2 (en) * 2012-05-25 2020-07-28 Sloan Kettering Institute For Cancer Research Methods for treating GI syndrome and graft versus host disease
US12655229B2 (en) * 2020-03-18 2026-06-16 Memorial Sloan Kettering Cancer Center Anti-ceramide antibodies

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100239572A1 (en) * 2007-05-06 2010-09-23 Sloan Kettering Institute For Cancer Research Methods for treating and preventing gi syndrome and graft versus host disease
US20190046538A1 (en) * 2007-05-06 2019-02-14 Sloan Kettering Institute For Cancer Research Methods for treating gi syndrome and graft versus host disease
WO2010027802A2 (en) * 2008-08-25 2010-03-11 New York University Methods for treating diabetic wounds
US20170335014A1 (en) * 2014-08-07 2017-11-23 Memorial Sloan-Kettering Cancer Center Anti-ceramide antibodies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ITAMAR GOREN等: "Systemic Anti-TNFa Treatment Restores Diabetes-Impaired Skin Repair in ob/ob Mice by Inactivation of Macrophages", JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 127, 26 April 2017 (2017-04-26), pages 2259 *

Also Published As

Publication number Publication date
CA3212333A1 (en) 2022-09-22
MX2023010858A (es) 2023-11-23
WO2022197703A1 (en) 2022-09-22
US20240158487A1 (en) 2024-05-16
IL305920A (en) 2023-11-01
EP4308231A4 (en) 2025-01-29
KR20230162788A (ko) 2023-11-28
JP2024511079A (ja) 2024-03-12
EP4308231A1 (en) 2024-01-24
BR112023018758A2 (pt) 2023-11-28

Similar Documents

Publication Publication Date Title
KR102887037B1 (ko) 호중구 질환을 치료하는 방법
CN114630842A (zh) 用于癌症治疗的结合her2、nkg2d和cd16的多特异性结合蛋白的药物制剂和剂量方案
JP2021193121A (ja) Ｉｌ−１７アンタゴニストを使用して汎発性膿疱性乾癬（ｇｐｐ）を処置する方法
JP2022126791A (ja) Ｉｌ－１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法
WO2008033495A2 (en) Method for detecting and treating skin disorders
CN119095617A (zh) 用于治疗患有头皮斑块型银屑病的受试者的方法
AU2022309469B2 (en) Il-13 antibodies for the treatment of atopic dermatitis
WO2023215769A1 (en) Il-13 antibodies for the treatment of atopic dermatitis
IL324054A (en) Pan-elr+ cxc chemokine antibodies for the treatment of hidradenitis suppurativa
US20240158487A1 (en) Wound healing enhancement with anti-ceramide antibodies
WO2019057982A1 (en) TREATMENT OF ATOPIC DERMATITIS
CN114746444A (zh) 使用白介素-17(il-17)拮抗剂治疗扁平苔藓的方法
JP2023543026A (ja) がんの処置のためのヒト化抗ｌｉｖ１抗体
JP2023547176A (ja) アトピー性皮膚炎又は関連症状を治療及び／又は防止するためのｉｌ－１８アンタゴニストの使用
CA3117142C (en) Pan-elr+ cxc chemokine antibodies for the treatment of hidradenitis suppurativa
JP2023177377A (ja) 多発性硬化症治療薬
RU2801204C2 (ru) Способ лечения атопического дерматита посредством введения ингибитора ил-4r
HK40048904A (en) Pan-elr+ cxc chemokine antibodies for the treatment of hidradenitis suppurativa
HK40048904B (en) Pan-elr+ cxc chemokine antibodies for the treatment of hidradenitis suppurativa
EA049484B1 (ru) Антитела против хемокинов pan-elr+ cxc для лечения гнойного гидраденита

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination